NVTA - NVTA インビティ ()


   Integrated Investment Consultants, LLC Buys SmileDirectClub Inc, iShares Core S&P 500 ETF, ...  2021/07/21 22:38:08 GuruFocus
Related Stocks: SDC , IVV , VONG , BSV , VOO , SCHD , XSOE , DOCN , GSK , FREL , JKH , SE , IAU , NVTA , BKNG , IAC , IGIB , MGNI ,
   Pacific Biosciences and Invitae Announce Intent to Expand Collaboration  2021/07/20 11:02:00 Intrado Digital Media
Collaboration to develop production-scale HiFi Sequencing platform expected to Include technology from Omniome, Inc.
   Bull of the Day: Exact Sciences (EXAS) | Investing.com  2021/07/19 11:20:06 Investing.com
Stocks Analysis by Zacks Investment Research covering: EXACT Sciences Corporation, Pacific Biosciences of California, InVitae Corp, Natera Inc. Read Zacks Investment Research''s latest article on Investing.com
   Vigilare Wealth Management Buys iShares Core Conservative Allocation ETF, iShares Russell 2000 ...  2021/07/16 12:38:04 GuruFocus
Related Stocks: AOK , IWM , F , GLD , BA , WMT , QCLN , SNOW , NVTA , DKNG , XLE , VGK , PBW , BND , AGG , USMV , KRE , AMT , SOLY , IAU , T , PENN , MPW , CCIV ,
   Prenatal Testing & Newborn Screening Market Research Report 2021 - ResearchAndMarkets.com  2021/07/16 11:35:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Prenatal Testing & Newborn Screening Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The market is expected to reach $8.018 billion in 2025 at a CAGR of 14%. Major players in the prenatal testing and newborn screening tests market are PerkinElmer, Progenity, Laboratory Corporation of America Holdings (Sequenom), Natera, Invitae, Centogene, Cradle Genomics, Roche Diagnostics, Quest Diagno
   Can Invitae Be the Winner-Take-Most in Genetic Testing?  2021/05/29 10:10:00 The Motley Fool
Just like in poker, in some markets, the winner can take the whole pot. Can Invitae take home all the chips?
   The Pullback In Pacific Biosciences Makes For A Much More Interesting Opportunity  2021/05/26 20:30:53 Seeking Alpha
   Facebook Takes Steps to Reduce Reach of Repeat Sharers of Misinformation  2021/05/26 20:05:00 Adweek
Facebook will begin showing prompts to users who are about to follow a page that has repeatedly shared content deemed to be false by its independent fact-checking partners. The popup will enable people to click and see more information about the social network's fact-checking program, as well as be notified that posts from that page…
   IVP is having a breakout year as ZipRecruiter becomes its 6th portfolio company to go public. And there are more to come, with companies like SoFi and Robinhood set to debut.  2021/05/26 19:26:02 Business Insider
Summary List Placement When IVP general partner Eric Liaw met the ZipRecruiter team in 2012, he found himself in a peculiar position. Most founders seek out investors like Liaw by submitting a pitch deck and formally pitching their startup ideas in hopes of raising money. But when he spoke with ZipRecruiter CEO Ian Siegel, whom Liaw was introduced to through a mutual friend in Los Angeles, it was clear that this particular startup didn't want, or need, his money. "He was like, 'I like you, but I don't need your money,' which is one of the things that I respect most about Ian," Liaw said. "Even in 2012, he was like, 'I don't want to bring an outsider into the company unless I have very concrete plans for what I would do with additional capital.'" After a two-year courtship, Liaw helped IVP lead an initial $63 million Series A round in August 2014 and followed up with subsequent rounds. The total number of ZipRecruiter shares IVP holds is 22.7 million, according to the firm. Based on Wednesday's opening price of $20 a share, that stake is now worth nearly $454 million. 10.5x multiple on invested capital from 2021 listings As later-stage venture-capital investors, the IVP team is described by VC peers and founders as being "specialized," "thoughtful," and "selective" about the investments it makes.
   Rich people are helping to fuel the venture capital boom by piling more of their money into newer venture firms  2021/05/26 19:17:56 Business Insider
Summary List Placement Recent splashy IPOs and eye-popping valuations have made venture capital — backing startups at their earliest stages — the place to be for all sorts of investors, including hedge funds and private equity firms. Family offices are increasingly getting in on the action, too, according to a report from Oper8r, a community for emerging venture firms, and First Republic Bank. Family offices, which manage the investments of the wealthy, are now allocating on average 24% of their funds into venture capital, the report says. That's a big jump from 2020, when they put in roughly 10% on average. In turn, most family offices are also co-investing directly into startups alongside the funds they back, with the most active ones making 20 investments a year. In this way, they can often buy shares in startups at a cheaper price than they would pay after the companies go public and anyone is able to invest. Interestingly, much of the money family offices are putting into venture capital is going to newer funds.
   We're really excited that these genomics companies, says Ark's Simon Barnett  2021/04/12 22:28:55 CNBC
Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.
   Invitae Accelerates Personalized Oncology Testing With Genosity Acquisition  2021/04/05 13:29:25 Benzinga
Invitae Corp (NYSE: NVTA ) has agreed to acquire Genosity Inc , a genomics company offering software and laboratory solutions to enable the development and deployment of complex sequencing-based tests. Deal consideration of approximately $200 million includes roughly $120 million in cash and roughly $80 million in Invitae common stock. Invitae is currently developing its Personalized Cancer … Full story available on Benzinga.com
   SoftBank leads $1.2 billion investment in diagnostics firm Invitae  2021/04/05 11:45:26 Investing.com
   Invitae Shares Are Trading Higher On SoftBank's Potential $1.2B Debt Investment: WSJ  2021/04/05 10:59:52 Benzinga
Japanese technology firm SoftBank Group Corp (OTC: SFTBY ) (OTC: SFTBF ) is planning to infuse around $1.2 billion via convertible debt into genetic-testing provider Invitae Corp (NYSE: NVTA ), the Wall Street Journal reports . The convertible debt investment will help Invitae to … Full story available on Benzinga.com
   Invitae introduces new program to increase access to genetic testing for adult neurodegenerative conditions  2021/04/01 11:30:00 Benzinga
SAN FRANCISCO , April 1, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA ), a leading medical genetics company, today announced the availability of sponsored genetic testing for patients in the U.S., Canada , Australia and Brazil who are suspected of having or are at risk for developing some of the most common adult neurodegenerative conditions, including Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and early-onset Alzheimer's disease (AD). The new program will make genetic testing available at no charge to individuals at risk for or suspected of having these difficult-to-diagnose conditions. Sponsored testing programs have been shown to increase access to genetic testing, which can help confirm a diagnosis, inform treatment and enable participation in clinical trials for patients. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)"> "As a …